戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 r cardiovascular endpoints and six for liver endpoints).
2          All-cause mortality was the primary endpoint.
3 e Categories (CPC) at 1 year was the outcome endpoint.
4 al response score at week 12 was the primary endpoint.
5 h PRO now represented in OWL and as a SPARQL endpoint.
6 several weeks before the time of the primary endpoint.
7  the dose was adjusted to attain the primary endpoint.
8 expenditure, food intake and other metabolic endpoints.
9 nd FibroTest were compared with histological endpoints.
10  vaccinating children for different settings/endpoints.
11 d progression-free survival were the primary endpoints.
12 cataract formation were determined as safety endpoints.
13 rate and time to recurrence were the primary endpoints.
14 ication at month 6 were defined as secondary endpoints.
15 , whereas 29 genes were associated with both endpoints.
16 vine PET on cancer control and late toxicity endpoints.
17 n FGF21 impact metabolic but not thermogenic endpoints.
18 illages would reach prevalence and intensity endpoints.
19  through the entire organoid, and functional endpoints.
20 ing system was independently associated with endpoint 1: HR, 2.14 (95% CI, 1.22-3.77).
21 ogic scoring systems on predicting composite endpoints 1 (PSC-related death and liver transplantation
22        All patients met the primary efficacy endpoint: 12 months after gene therapy, PDMS-2 scores we
23 hak system: HR, 1.55 [95% CI, 1.10-2.18] for endpoint 2 and HR, 1.43 [95% CI, 1.10-1.85] for endpoint
24 95% confidence interval (CI), 1.49-6.68] for endpoint 2 and HR, 2.05 [95% CI, 1.17-3.57] for endpoint
25 wig system: HR, 2.62 [95% CI, 1.19-5.80] for endpoint 2 and HR, 2.06 [95% CI, 1.09-3.89] for endpoint
26 aging systems were independent predictors of endpoints 2 and 3 (Nakanuma system: hazard ratio [HR], 3
27 point 2 and HR, 2.06 [95% CI, 1.09-3.89] for endpoint 3).
28 point 2 and HR, 2.05 [95% CI, 1.17-3.57] for endpoint 3; Ishak system: HR, 1.55 [95% CI, 1.10-2.18] f
29 point 2 and HR, 1.43 [95% CI, 1.10-1.85] for endpoint 3; Ludwig system: HR, 2.62 [95% CI, 1.19-5.80]
30 igher rates of the device-oriented composite endpoint (3.3% [69 of 2100] vs 1.9% [23 of 1193]; RR 1.6
31                Studies reporting the primary endpoint, 30-day post-operative stroke rate, were includ
32 s statistically improves prediction for some endpoints, absolute changes and impact on clinical decis
33 ted novel biomarkers and clinically relevant endpoints across a spectrum of warm ischemic times, befo
34 atio (TBR) from the ascending aorta (primary endpoint) (adalimumab: TBR = 0.002, 95% confidence inter
35 he relevant endpoint (RE) and the additional endpoint (AE).
36 s not evident from analysis of developmental endpoints alone, including pulsatile frequency-modulated
37                      The key exploratory PRO endpoints (analysed for all patients who received at lea
38                         The primary efficacy endpoint, analysed in the per-protocol population, was p
39 were classified were included in the primary endpoint analysis.
40 ug combinations were assessed on >1 phase 2A endpoint and only 3 were assessed in both phase 2A and 2
41 iteria for inclusion (one for cardiovascular endpoints and six for liver endpoints).
42 recent RCT, in which ICU LOS was the primary endpoint, and in administrative data, we showed that add
43 rovide core principles, appropriate clinical endpoints, and endpoint definitions to be used in clinic
44 nt of cardiac biomarkers and other surrogate endpoints, and in some cases initiation of cardioprotect
45                               The predefined endpoints are 30- and 360-day complications, and shocks
46                      The underlying clinical endpoints are analysed in seasonal time periods predefin
47  the currently used endpoints, potential new endpoints, as well as what new markers are needed to ass
48                                  The primary endpoints assessed at the end of treatment were the safe
49 ent for a device-oriented composite clinical endpoint at 12 months in an all-comer population.
50  Study monitoring was monthly to the primary endpoint at month 12 and then protocol-driven follow-up
51 the tight control group achieved the primary endpoint at week 48 (56 [46%] of 122 patients) than in t
52      Treatment allocation was open label but endpoints at 12 months were assessed by masked investiga
53                          The study's primary endpoint, at week 24, was previously reported (combined
54 clinical events committee adjudicated safety endpoints based on Valve Academic Research Consortium-2
55 e no significant differences in major 30-day endpoints between the 2 groups.
56                      The primary performance endpoint, biventricular pacing on the 12-lead electrocar
57                     We aimed to establish an endpoint capturing clinically relevant deteriorations (d
58 me measure was the device-oriented composite endpoint (cardiac mortality, target vessel-related myoca
59    Baseline echocardiography and a composite endpoint (cardiovascular mortality and hospitalization)
60        Here, we sequenced the genomes of one endpoint clone from each population to test whether the
61 ty of tolvaptan over placebo for the primary endpoint compared with patients with these findings.
62 le size analysis, in which g was used as the endpoint, compared docetaxel data with mitoxantrone data
63                         Changes in composite endpoint components were not significantly different bet
64                                    Secondary endpoints consist of the development of gallstones on ul
65 text of pharmacogenetics, where the survival endpoint could be death, disease remission or the occurr
66                                     Clinical endpoints defined as hepatic decompensation (ascites, en
67 nciples, appropriate clinical endpoints, and endpoint definitions to be used in clinical trials of PV
68 sease severity, data collection, and updated endpoint definitions.
69 nt of disease severity, data collection, and endpoint definitions.
70  over investigator's choice therapy (primary endpoint; described previously).
71                                  The primary endpoint did not differ significantly between the ASV an
72 , and physiologic consequences of automated, endpoint-directed resuscitation systems and compare them
73 reby accelerate progress towards the desired endpoint (e.g., elimination) or increase the chances of
74 (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnesota Living with Hear
75                                  The primary endpoint, equivalence of overall response, was met (271
76 oice of animal models, selecting appropriate endpoints, ethics of informed consent, and regulatory is
77 d chemicals was determined using biochemical endpoints, exposure activity ratios for biological and e
78 and each OCT scan was linked to EMR clinical endpoints extracted from EPIC.
79 of DNA damage signaling in vitro could be an endpoint for developing whole mixture potency factors (M
80                                  The primary endpoint for efficacy was biochemical response as define
81                                  The primary endpoint for this study was a time-dependent composite o
82 ognostication, and to determine intermediate endpoints for clinical trials.
83 ntrahepatic cccDNA and/or HBsAg are critical endpoints for future antiviral therapy in chronic HBV.
84                                The coprimary endpoints for noninferiority were hemagglutination inhib
85    To address this lack, we mapped resection endpoints genome-wide at high resolution in Saccharomyce
86 : 1.04 to 1.49; p = 0.020) and the composite endpoint (HR: 1.21; 95% CI: 1.05 to 1.40; p = 0.010).
87 e greatest risk of adverse outcomes: primary endpoint (HR: 2.21; 95% CI: 1.80 to 2.71), HF hospitaliz
88                                  The primary endpoint in both populations was overall survival (defin
89           Loss of photoreceptors is a common endpoint in degenerative retinal diseases.
90 blish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer.
91    Post-hoc analysis of survival to combined endpoint in SMA infants with 2 copies of SMN2 indicated
92 n is hampered by lack of a feasible clinical endpoint in this population.
93 ctiveness (RBE) factors for surrogate cancer endpoints in cell culture models and tumor induction in
94 ions and raises the question of the relevant endpoints in clinical studies.
95 r noninvasive monitoring and as quantitative endpoints in early intervention trials in children with
96 zes for subacute and chronic neurobehavioral endpoints in other domains, however, were small.
97 h lower than expected, rendering the primary endpoint inadequately powered.
98                                    Secondary endpoints included IVF- and LD-related safety, such as b
99                                        Other endpoints included mean number of annual injections and
100                                        Study endpoints included myocardial infarction, new or worseni
101                                              Endpoints included noninferiority of HPV-16/18 antibodie
102                                    Secondary endpoints included SSI incidence at 4 days, length of st
103                       CSDS affected numerous endpoints, including paradoxical sleep (PS) and slow-wav
104                     Although the most common endpoint is a reduced number of eosinophils in biopsies,
105 ly changing their gait, which could bias the endpoint measures.
106 patients in the cohort, 2616 met the primary endpoint (median time to event of 14.5 years) and 721 de
107  sample sizes, longer duration, or a primary endpoint more sensitive in this pre-dementia population,
108                              For the primary endpoint, multilevel modelling yielded significantly hig
109  patients with non-completion of the primary endpoint, non-compliance to treatment (ascertained by pa
110                                          The endpoint occurred in 6.6% of prasugrel patients and in 5
111   At 4-year follow-up, the primary composite endpoint occurred in 61%.
112 st independent CMR predictor of the combined endpoint (odds ratio: 2.73; 95% confidence interval: 1.2
113  an intention-to-treat analysis, the primary endpoint of air leak duration was not different between
114  infection, which was defined as a composite endpoint of bacterial pneumonia (confirmed by the endpoi
115 oeboid movement may thus constitute a common endpoint of both EMT-dependent and EMT-independent cance
116 red with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction,
117       There was no difference in the primary endpoint of day 1 dyspnea reduction, despite significant
118 y visit was associated with risk of combined endpoint of death or permanent invasive ventilation in S
119 ssociated with a lower risk for the combined endpoint of HF readmission or all-cause mortality (HR: 0
120 ctors that predict relapse risk (the primary endpoint of many pivotal clinical trials testing the eff
121  up volunteers for 24 months for the primary endpoint of safety, assessed as local and systemic react
122 roportion of individuals meeting the primary endpoint of seroconversion for poliovirus types 1, 2, an
123                        For the key secondary endpoint of sweat chloride concentration, the least squa
124                               The predefined endpoint of the 5-year analysis was invasive disease-fre
125 mortality rate in the liberal group (primary endpoint of the study) was 45% (67 patients) versus 56%
126                                  The primary endpoint of this trial was to establish the proportion o
127               Group differences on secondary endpoints of disease progression measuring cognition and
128 pical corticosteroids achieved the coprimary endpoints of IGA 0/1 (39% [125 patients] who received du
129                          Currently available endpoints of therapy are inadequate to evaluate the effi
130  examined for association with a traditional endpoint (overall survival) and for its potential use as
131 n this review, we discuss the currently used endpoints, potential new endpoints, as well as what new
132 imination index (IDI) were applied to assess endpoint prediction.
133 Although this study did not meet its primary endpoints, prespecified subgroup analyses of patients wi
134                            As an exploratory endpoint, PROs were assessed at baseline, week 9, and ev
135 llel group, superiority, open-label, blinded-endpoint, randomised controlled trial, patients aged 70
136 nts and a CE with 2 components: the relevant endpoint (RE) and the additional endpoint (AE).
137 patients, respectively, achieved the primary endpoint (relative risk 1.76, 95% CI 1.12-2.77, p=0.0045
138 us in vivo measurement of multiple metabolic endpoints remains challenging.
139 s results were inconsistent with the primary endpoint result; further research into the role of compl
140 int of bacterial pneumonia (confirmed by the endpoint review committee), pulmonary or extrapulmonary
141 le to stimulate GSK3beta phosphorylation, an endpoint robustly activated by the full-length receptor.
142 thout confirmed influenza, and 13 without an endpoint sample.
143                                  The primary endpoint, sensitivity of the sentinel-lymph-node-based d
144 participants were assessable for the primary endpoint (sodium thiosulfate, n=49; control, n=55).
145 nventional therapy using a stringent primary endpoint (steroid-free clinical remission for 3 months w
146                                       Use of endpoints, such as sleep and circadian rhythm, that are
147  had deterioration in the QLQ-LC13 composite endpoint than did chemotherapy-treated patients (46 [31%
148 n patients enrolled in the ASTIC trial using endpoints that are traditional for clinical trials in Cr
149 us surgical procedures while exploring trial endpoints that may be optimal for each tumor type.
150                              For the primary endpoint, the average absolute change in LCI2.5 from bas
151                                     For both endpoints, the between-group differences were statistica
152 10(7) PFU dose, the geometric mean IgG ELISA endpoint titre was 1624 (95% CI 1146-2302) and seroconve
153 genomes de novo fail to achieve the ultimate endpoint to produce contigs, each representing one whole
154 ll survival) and for its potential use as an endpoint to reduce sample size in clinical trials.
155  (the combination being our a priori primary endpoint), to provide context and enhance precision of p
156 prospective, randomised, open-label, blinded-endpoint trial in adult participants with ischaemic stro
157                           We evaluated these endpoints using log-binomial regression, adjusting for t
158 were obtained at week 26 from all 25 primary endpoint vaccine cases and 125 matched vaccine controls,
159 h 14.9 [SD=9.2]; adjusted beta=-5.91) at the endpoint visit.
160                                  The primary endpoint was >/=20% reduction in heart rate from baselin
161                         The primary efficacy endpoint was 1-year change in MLMT performance, measurin
162                                  The primary endpoint was 2 year event-free survival in all registere
163                                  The primary endpoint was 30-day all-cause mortality.
164                                  The primary endpoint was 90-day mortality.
165                                  The primary endpoint was a >/=50% improvement on the Pain Disability
166                                  Our primary endpoint was a 3-year composite outcome of posttransplan
167                                  The primary endpoint was a 7-point change in self-assessed dyspnea a
168                         The primary efficacy endpoint was a 75% reduction in PASI score (PASI 75) fro
169                                  The primary endpoint was a composite global rank score (hierarchy of
170                           The primary safety endpoint was a composite of cardiac death, myocardial in
171                                  The primary endpoint was a composite of myocardial infarction, strok
172                                  The primary endpoint was a reduction by at least 35% in the spleen v
173                  INTERPRETATION: The primary endpoint was a useful means of measuring clinical perfor
174                                  The primary endpoint was all-cause mortality at 30 days.
175 th from cardiovascular causes; the secondary endpoint was all-cause mortality.
176 was death-censored graft loss, and secondary endpoint was all-cause mortality.
177                                  The primary endpoint was annualised relapse rate.
178                                  The primary endpoint was annualized rate of kidney enlargement in pa
179                                  The primary endpoint was assessed in all patients who received at le
180                                 The combined endpoint was cardiovascular death, MI, or stroke at 1 ye
181                                  The primary endpoint was change from baseline to Day 84 on a semiqua
182                         The primary efficacy endpoint was change from baseline to week 6 in the 80 mg
183                                  The primary endpoint was change in 6MWD from baseline to week 48.
184                                  The primary endpoint was change in Asthma Control Questionnaire (ACQ
185                                  The primary endpoint was clinical cure at the test-of-cure visit (21
186                         The primary efficacy endpoint was clinically driven target lesion revasculari
187                                  The primary endpoint was comparability in overall response, with equ
188                                      Primary endpoint was death-censored graft loss, and secondary en
189                          The imaging primary endpoint was detection of early subclinical engraftment
190                                  The primary endpoint was difference in exercise time increment betwe
191                                  The primary endpoint was disease-free survival at 10 years of follow
192                                  The primary endpoint was failure of the treatment strategy, defined
193                                  The primary endpoint was failure, defined as death related to infect
194                                  The primary endpoint was favorable neurocognitive outcome (cerebral
195                                  The primary endpoint was final infarct size.
196                         The primary efficacy endpoint was global stroke recovery, which combines dich
197                                  The primary endpoint was HBV reactivation, defined as detectable HBV
198                                  The primary endpoint was healing rates of HD-CU at 14 days after tre
199                                  The primary endpoint was incidence of grade 2 or worse stomatitis by
200                                  The primary endpoint was incidence of hearing loss 4 weeks after fin
201                                  The primary endpoint was independently confirmed objective response
202                                      Primary endpoint was inpatient mortality.
203                                  The primary endpoint was intestinal permeability in patients with sy
204                                  The primary endpoint was investigator-assessed intracranial response
205                                  The primary endpoint was investigator-assessed progression-free surv
206                                  The primary endpoint was investigator-assessed progression-free surv
207                                  The primary endpoint was ipsilateral local relapse (80% power to exc
208                                  The primary endpoint was Kaplan-Meier survival to transplant.
209 e survival and overall survival; the primary endpoint was later changed to overall survival after the
210                                  The primary endpoint was met in 27 of 30 patients (90%).
211                         The primary efficacy endpoint was met with clemastine fumarate treatment, whi
212                                  The primary endpoint was moderate-to-severe COPD exacerbation rate.
213                                  The primary endpoint was mucosal healing (CDEIS <4) with absence of
214                                  The primary endpoint was not achieved (P = 0.072); however, a greate
215  in 767 patients, the noninferiority primary endpoint was not achieved (p value for noninferiority =
216                                  The primary endpoint was ocular and systemic safety, but exploratory
217                                  The primary endpoint was overall response, defined as the proportion
218                                  The primary endpoint was overall survival in the intention-to-treat
219                                  The primary endpoint was overall survival in the intention-to-treat
220                                  The primary endpoint was overall survival, analysed by intention to
221                                  The primary endpoint was oxygenation index (OI) at day 7.
222                                  The primary endpoint was participation (ie, attendance at breast can
223                                  The primary endpoint was percentage change from baseline in areal BM
224                                      Primary endpoint was postoperative pelvic sepsis within 30 posto
225                                  The primary endpoint was progression-free survival assessed by an in
226                                  The primary endpoint was progression-free survival by local investig
227                                  The primary endpoint was progression-free survival by local investig
228                                  The primary endpoint was proportion of responders.
229                                  The primary endpoint was reached in 188 patients (40%) during a medi
230                                  The primary endpoint was safety and ORR.
231          In the meta-analysis, the composite endpoint was similar between groups (hazard ratio [HR]:
232                                  The primary endpoint was spleen response (defined as the proportion
233                                  The primary endpoint was sustained virologic response 12 weeks after
234                         The primary efficacy endpoint was sustained virological response at post-trea
235                         The primary efficacy endpoint was the change from baseline in behavioral symp
236                                  The primary endpoint was the change from baseline in total renal art
237                                  The primary endpoint was the change of serum bilirubin, creatinine a
238                         The primary efficacy endpoint was the composite of all-cause mortality, myoca
239                       The secondary efficacy endpoint was the composite of cardiovascular death, myoc
240                            The primary HRQoL endpoint was the global health scale, with the predefine
241                                  The primary endpoint was the incidence of serious adverse events at
242                                  The primary endpoint was the mean change from baseline in the St Geo
243                                  The primary endpoint was the number and percentage of adverse events
244                         The primary efficacy endpoint was the number of attacks of hereditary angio-o
245                                  The primary endpoint was the occurrence of SSI within 30 days of sur
246                         The primary efficacy endpoint was the percentage of patients with a sustained
247                                  The primary endpoint was the proportion of participants with less th
248                                  The primary endpoint was the proportion of participants with plasma
249                                  The primary endpoint was the proportion of participants with plasma
250                                  The primary endpoint was the proportion of patients achieving an obj
251                                  The primary endpoint was the proportion of patients in each group wi
252                                  The primary endpoint was the proportion of patients in the intention
253                                  The primary endpoint was the proportion of patients who attained an
254                                  The primary endpoint was the rate of uncomplicated perineal wound he
255                                  The primary endpoint was the time to occurrence of stroke, myocardia
256                                  The primary endpoint was time to culture conversion in liquid media
257                                  The primary endpoint was time to local recurrence in the resection c
258                                  The primary endpoint was time to normalisation of patients' respirat
259                                  The primary endpoint was time to progression (time of progressive di
260                         The primary efficacy endpoint was time to recurrence of any mood event during
261                         The primary efficacy endpoint was time-to-parasitaemia, assessed by TBS.
262                                  The primary endpoint was WHO-defined radiological pneumonia with pul
263 defined as responders at 24 h (primary study endpoint) was 16% for tolvaptan and 20% for placebo (p =
264 l was negative for its primary and secondary endpoints, we did observe significant differences in mul
265             Correlates of the primary safety endpoint were age, anemia, congestive heart failure, mul
266 eated biomarker measurements and the primary endpoint were assessed using a joint model.
267          The main predictors for the primary endpoint were male sex (p = 0.022), NYHA functional clas
268                                      Primary endpoints were 2 quality-of-life measurements, the Kansa
269                               The co-primary endpoints were adequate relief of symptoms and stool Bif
270                                       Safety endpoints were adverse events, clinical laboratory value
271        Pharmacokinetic, safety, and virology endpoints were also assessed.
272                                        These endpoints were analysed in the intention-to-treat popula
273                                The secondary endpoints were antitumor effect and safety (UMIN00000944
274 569 deaths (26.2%) and 896 (41.2%) composite endpoints were ascertained.
275                                The secondary endpoints were changes in pruritus scores measured using
276  from whom DNA and dental and anthropometric endpoints were collected during multiple examinations (a
277                                      Primary endpoints were DSM265 safety, tolerability, and pharmaco
278 tions between AD status and cardio-metabolic endpoints were estimated using survey weighted logistic
279                                      Primary endpoints were frequency of recommending shorter (3-year
280                                  The primary endpoints were maximum tolerated dose and dose-limiting
281                                    Coprimary endpoints were overall survival in the intention-to-trea
282                                              Endpoints were patient survival +/- liver transplant and
283                                    Coprimary endpoints were patients (%) achieving Investigator's Glo
284                                The secondary endpoints were physiological parameters, duration of ven
285                                    Secondary endpoints were postoperative wound infection, intra-abdo
286                                   Co-primary endpoints were progression-free survival and overall sur
287                                   Co-primary endpoints were progression-free survival in patients wit
288                                      Primary endpoints were safety and tolerability for the escalatio
289                                      Primary endpoints were safety and tolerability, analysed in the
290                                  The primary endpoints were safety of GSK2330672, assessed using clin
291                                              Endpoints were short- and long-term survival rates.
292                                              Endpoints were survival, life expectancy, quality-adjust
293                                The key study endpoints were technical success assessed at the end of
294                                    Secondary endpoints were the change in infarct volume from baselin
295                                     The main endpoints were the change in mean and median best-correc
296                                  The primary endpoints were the first record of 1 of 4 cardiovascular
297                                  The primary endpoints were the proportion of patients in the ITG wit
298                                      Primary endpoints were the proportion of positive section margin
299                               The co-primary endpoints were treatment failure (histological progressi
300                                        Study endpoints were: incidence of adverse events, incidence o

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top